ProCE Banner Activity

CUSTOMIZE: Implementation-Effectiveness Study of Long-Acting Cabotegravir and Rilpivirine Injection in US Healthcare Settings

Slideset Download
Conference Coverage
In this real-world study, healthcare staff across a variety of clinic types found the implementation of monthly injectable cabotegravir + rilpivirine both feasible and acceptable despite disruptions due to COVID-19.

Released: July 22, 2021

Expiration: July 21, 2022

No longer available for credit.

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Gilead Sciences, Inc.

Janssen Therapeutics Division of Janssen Products

Merck Sharp & Dohme Corp.

ViiV Healthcare

Partners

IAS 2021

ProCE Banner